Quantcast

Latest European League Against Rheumatism Stories

2012-06-07 11:56:18

Results of a systematic review urge prophylactic treatment for those at risk Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumor necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism. "Anti-TNFs, such as...

2012-06-07 11:54:21

For every additional 6 months of treatment CV risk reduces further Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumor necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid...

2012-06-07 11:52:07

Threat of epidemic as this population increases A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled. Via the Nationwide Inpatient Sample (NIS), 4.3 million patients over the age of 65 with osteoporotic hip fractures were studied. Results showed that 67.3% of...

2012-06-07 11:50:32

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by 2,595,557 per 272 patients over 3 years (95 percentile range -2,983,760 to -2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs). Cost savings were mostly on drug costs. The Dutch study, which investigated 272 patients...

2012-06-06 12:30:57

Safety results were similar between groups Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24. The ADACTA trial, conducted in 325 patients with RA showed that tocilizumab was more effective than adalimumab for DAS28 remission (39.9%...

2012-06-06 12:28:10

Further data reveals there is no consistent criteria for biologic reimbursement in place Data from a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates the vast inequalities in access to biologics for the treatments of rheumatoid arthritis (RA) across 46 European countries, with 22% (n=10) of countries having no biologic reimbursed at all. In the 36 countries with reimbursed biologics, only 27 had more than five biologics...

2012-06-06 12:26:10

Study identifies 5 biomarkers A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, has identified five biomarkers that may predict the progression of structural damage in the spine of patients with Ankylosing Spondylitis (AS) who are already at high risk of disease progression. The German study analysed 64 patients from the German Spondyloarthritis Inception Cohort (GESPIC), due to the presence of radiographic spinal damage...

2011-05-25 15:45:00

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK. Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination...

2011-05-25 14:36:39

Data presented at EULAR Annual European Congress of Rheumatology Crescendo Bioscienceâ“ž¢ today announced data indicating that Vectraâ“ž¢ DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis (RA) disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy. Additional studies show that the score from the Vectra DA algorithm has the...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related